menu
    • menu
    [{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"LX1004","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ Longitude Capital","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Longitude Capital"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Adverum Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"LX2006","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lexeo Therapeutics \/ LEXEO Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Lexeo Therapeutics \/ LEXEO Therapeutics"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"LX2006","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"LX2022","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ LEXEO Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lexeo Therapeutics \/ LEXEO Therapeutics"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"LX1004","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"D1 Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"LX2006","moa":"FXN gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ D1 Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ D1 Capital Partners"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAVrh.10hAPOE2","moa":"Apolipoprotein E 2\/3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAVrh.10hAPOE2","moa":"Apolipoprotein E 2\/3","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"LX1001","moa":"APOE2 gene","graph1":"Neurology","graph2":"Phase I","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"LX1004","moa":"TPP1","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAVrh.10hFXN","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Cerveau Technologies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"AAVrh.10hAPOE2","moa":"APOE4 gene","graph1":"Neurology","graph2":"Phase I","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lexeo Therapeutics \/ LEXEO Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Lexeo Therapeutics \/ LEXEO Therapeutics"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"LX2006","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"AAVrh10-based Gene Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"LX2021","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ Sarepta Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Lexeo Therapeutics \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"LX2006","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"LX2006","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"LX2006","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"LX2020","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"LX2006","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"LX2006","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Lexeo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Lexeo Therapeutics"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"LX2006","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Lexeo Therapeutics

    Menu

    Lexeo Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lexeo Therapeutics Reports Positive Interim Phase 1/2 Data of LX2006 for Friedreich Ataxia

                            Details : LX2006 is an AAV-based gene therapy candidate & designed to deliver a functional frataxin gene. It is being evaluated for the treatment of friedreich’s ataxia cardiomyopathy.

                            Brand Name : LX2006

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 15, 2024

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Recipient : Cornell University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lexeo Therapeutics Announces License Agreement for LX2006 for Friedreich Ataxia

                            Details : Lexeo Therapeutics acquires IP rights to LX2006 (AAVrh.10hFXN) gene therapy for Friedreich ataxia cardiomyopathy.

                            Brand Name : LX2006

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 22, 2024

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Cornell University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lexeo Therapeutics Receives FDA Fast Track Designation for LX2006 for Friedreich's Ataxia

                            Details : LX2006 is an AAV-based gene therapy candidate & designed to deliver a functional frataxin gene. It is being evaluated for the treatment of friedreich’s ataxia cardiomyopathy.

                            Brand Name : LX2006

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 16, 2024

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $95.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

                            Details : Lexeo will use net proceeds to advance clinical programs, including LX2006, a gene therapy candidate aimed at delivering a functional frataxin gene for FA cardiomyopathy.

                            Brand Name : LX2006

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 13, 2024

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $95.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $95.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

                            Details : Lexeo intends to use proceeds to advance ongoing clinical stage programs, including LX2006, a gene therapy candidate designed to deliver a functional frataxin gene for treating FA cardiomyopathy.

                            Brand Name : LX2006

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 11, 2024

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $95.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX2020

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gen...

                            Details : LX2020 is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional PKP2 gene to cardiac muscle, which is under phase 1/2 clinical development for the treatment of arrhythmogenic cardiomyopathy (ACM) caused by mutations in th...

                            Brand Name : LX2020

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 18, 2023

                            Lead Product(s) : LX2020

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Lexeo Therapeutics Announces Pricing of Initial Public Offering

                            Details : The proceeds will advance the development of LX2006, LX2020 and LX1001 and will fund the continued development of other programs and cardiac discovery efforts. LX2006 is an AAV-based gene therapy candidate delivered intravenously for the treatment of FA ...

                            Brand Name : LX2006

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 02, 2023

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX2021

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Discovery

                            Sponsor : Sarepta Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            LEXEO Therapeutics Announces Strategic Investment from Sarepta Therapeutics to Support Development of LEXEO's ...

                            Details : In connection with this investment, the companies will explore the development of novel gene therapy candidates, including LX2021 and LX2022 for a range of cardiovascular diseases.

                            Brand Name : LX2021

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 28, 2023

                            Lead Product(s) : LX2021

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Discovery

                            Sponsor : Sarepta Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAVrh10-based Gene Therapy

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LEXEO Therapeutics Announces FDA Clearance of IND for LX2020, an AAV-based Gene Therapy Candidate for PKP2 Arr...

                            Details : LX2020 is designed to intravenously deliver a functional PKP2 gene to cardiac muscle to increase PKP2 protein levels in the cardiac desmosome, a cell structure critical for cell adhesion.

                            Brand Name : LX2020

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 01, 2023

                            Lead Product(s) : AAVrh10-based Gene Therapy

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Lexeo Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2...

                            Details : LX2006 is an AAV-based gene therapy candidate delivered intravenously and designed to target the cardiac manifestations of FA by delivering a functional frataxin gene to promote the expression of the frataxin protein and restore mitochondrial function in...

                            Brand Name : LX2006

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 13, 2023

                            Lead Product(s) : LX2006

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth